Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
$1.99
per week
for 24 weeks
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Merck & Company NYSE: MRK-N

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 75.55
Day High 76.26
Open:75.85
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Join Science 37 for a Panel of Health Industry Leaders Exploring "Decentralized Clinical Trials and the Empowered Patient Trial Experience" at Reuters Webinar
- Business Wire - Wed Jun 23, 9:39AM CDT
Business Wire - CMTX
Wed Jun 23, 9:39AM CDT
Science 37 CEO David Coman alongside executives from Bayer, Sanofi, Merck and Pluto Health will discuss how to build an operating system to ensure patient preferences drive a decentralized clinical trial (DCT) approach during an upcoming Reuters Webinar.
Praxis Bioresearch Announces Positive Results from Clinical Microdose Study in Humans Showing Oral Activation of Its Novel Prodrug Stimulant PRX-P4-003
- GlobeNewswire - Wed Jun 23, 5:07AM CDT
GlobeNewswire - CMTX
Wed Jun 23, 5:07AM CDT
Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous system disorders, today announced that it has successfully completed a microdose study in healthy volunteers under an exploratory IND approved by FDA in January 2021.
Parkinson’s Dyskinesia Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2025
- Heraldkeepers - Tue Jun 22, 12:12PM CDT
Heraldkeepers - CMTX
Tue Jun 22, 12:12PM CDT
Parkinson's disease is a long term neurodegenerative disorder which affects the dopamine producing neurons in specific areas of the brain known as substantia nigra. This disease belongs to a group of conditions called motor system disorders. The symptoms for Parkinson's disease develop slowly over the years. The four primary symptoms of Parkinson's disease are tremors, rigidity, slowness of movement and postural instability.Stiff limbs and tremors might be familiar symptoms if you have Parkinson’s disease. You may also have other movements you can't control — like swaying, head bobbing, or fidgeting. These are signs of a condition called dyskinesia.This report elaborates the market size, market characteristics, and market growth of the Parkinson’s Dyskinesia industry, and breaks down according to the type, application, and consumption area of Parkinson’s Dyskinesia. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 72.07 +5.10% increase
on 06/08/21
Period Open:79.18
Price movement based on the high, low and last over the given period.
79.65 -4.90% decrease
on 05/24/21
-3.43 (-4.33%) decrease
since 05/21/21
3-Month 72.07 +5.10% increase
on 06/08/21
Period Open:76.27
Price movement based on the high, low and last over the given period.
80.34 -5.71% decrease
on 05/21/21
-0.52 (-0.68%) decrease
since 03/23/21
52-Week 71.71 +5.63% increase
on 03/04/21
Period Open:77.12
Price movement based on the high, low and last over the given period.
87.80 -13.72% decrease
on 09/03/20
-1.37 (-1.78%) decrease
since 06/23/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies